Decoy Therapeutics CEO to Present at June 11 hVIVO London Capital Markets Day
DCOY•Decoy Therapeutics CEO Rick Pierce will speak at hVIVO Capital Markets Day on June 11 in London alongside Boehringer Ingelheim and RA Capital, focusing on early clinical development strategies and human challenge trial frameworks. The company’s AI-enabled IMP³ACT platform is advancing Designable Multi-Antiviral candidates, led by a pan-coronavirus program targeting clinic entry in 2027.
1. CEO Participation at Capital Markets Day
Rick Pierce, Chief Executive Officer of Decoy Therapeutics, will join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies at hVIVO’s half-day event on June 11 at Canary Wharf, London. The session gathers analysts, institutional investors and media to discuss partnerships that accelerate early drug development.
2. Emphasis on Early Clinical Development Strategies
Pierce will highlight the strategic role of human challenge trials and specialized partner engagement in expediting novel antiviral candidates from concept to clinic. Discussions will explore how such models enhance decision-making speed and data quality during Phase I studies.
3. Progress of the D-MAV Pipeline
Decoy’s AI-enabled IMP³ACT platform is driving its pipeline of Designable Multi-Antivirals, engineered to target conserved viral mechanisms across families. The lead pan-coronavirus program is on track for clinical entry in 2027, aiming to provide a single adaptable therapeutic against multiple respiratory viruses.
